COMMUNIQUÉS West-GlobeNewswire

Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts
17/11/2025
Curium Biopharma will continue to lead discovery and new product development Strategic move aims to accelerate biopharma innovation and revolutionize the diagnosis and treatment of cancer Curium International [...]
T-knife Therapeutics Files Clinical Trial Application for Phase 1 ATLAS Trial for TK-6302, a Supercharged PRAME-targeted T Cell Receptor Therapy
17/11/2025
-- Preclinical data with TK-6302 has shown best-in-class anti-tumor efficacy, demonstrating its potential to elicit deep and durable responses in diverse solid tumor indications with high unmet need -- Following CTA [...]
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
17/11/2025
Extends cash runway into first half of 2027, beyond planned first half of 2026 proof of concept (“POC”) data readouts of SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC) Led by Ikarian Capital, Squadron Capital Management, [...]
Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit
17/11/2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection [...]
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
17/11/2025
CONSHOHOCKEN, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: Jefferies [...]
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101
17/11/2025
- Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) - - AAV- [...]
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
17/11/2025
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026 If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 [...]
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
17/11/2025
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with [...]
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
17/11/2025
LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update
17/11/2025
NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive correspondence from FDA, and expects Q2 2026 GDUFA date. HOPE Therapeutics is now operating three [...]
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
17/11/2025
SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it [...]
Ashvattha Therapeutics to Showcase Topline Phase 2 Data and Recent FDA Alignment at Upcoming Investor and Ophthalmology Meetings
17/11/2025
Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being developed for the treatment of DME and nAMD FDA alignment on Phase 2b/3 trial [...]
Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy
17/11/2025
System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year [...]
Halda Therapeutics Announces Acquisition by Johnson & Johnson
17/11/2025
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical [...]
INVO Fertility Announces Third Quarter 2025 Financial Results
17/11/2025
SARASOTA, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition and operation of [...]
TOMI Environmental Solutions, Inc. Announces Filing of $50 Million Universal Shelf Registration Statement and Equity Line of Credit
17/11/2025
FREDERICK, Md., Nov. 17, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® ( [...]
Veri Medtech (VRHI) Files Registration Statement for Proposed Initial Public Offering
17/11/2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OTC Markets -- Veri Medtech Holdings, Inc. (Stock Ticker Symbol: “ VRHI ”) ("Veri Medtech"), healthcare technology platform, announced today that it has filed a registration [...]
SeaStar Medical Announces Appointment of Michael Messinger as CFO
17/11/2025
DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
17/11/2025
MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, [...]

Pages